Aastrom Biosciences Appoints Daniel R. Orlando as Chief Commercial Officer
September 05 2012 - 8:00AM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of
patient-specific, expanded multicellular therapies for the
treatment of severe, chronic cardiovascular diseases, today
announced the appointment of Daniel (Dan) R. Orlando as chief
commercial officer, a newly created position at Aastrom.
Most recently, Dan was with Takeda Pharmaceuticals for over 13
years in executive leadership positions in marketing, sales and
business development, most recently as vice president, business
development for North and South America. Previously, he was with
Abbott Laboratories for more than 11 years in progressive sales and
marketing roles. During his career, he has helped to establish
dozens of pharmaceutical brands including, most significantly,
Actos®. Under Dan's leadership,
Actos® became the top brand in diabetes. Dan
holds an M.B.A. in management from Florida Atlantic University and
a Bachelor of Science degree from the University of
Florida.
"Aastrom's experienced team, compelling Phase 2b clinical
results and Phase 3 status, combined with overall leadership in the
development of cellular therapies, attracted me to the company,"
said Dan.
"Dan has proven success in product and business development in
the metabolic field and his experience will positively support the
next stage of development for ixmyelocel-T. We are very pleased to
have Dan on board as we work to position ixmyelocel-T for FDA
review, approval and commercialization," said Tim Mayleben,
Aastrom's president and chief executive officer.
About Aastrom Biosciences
Aastrom Biosciences is the leader in developing
patient-specific, expanded multicellular therapies for use in the
treatment of patients with severe, chronic cardiovascular
diseases. The company's proprietary cell-processing technology
enables the manufacture of ixmyelocel-T, a patient-specific
multicellular therapy expanded from a patient's own bone marrow and
delivered directly to damaged tissues. Aastrom has advanced
ixmyelocel-T into late-stage clinical development, including a
Phase 3 clinical program to study patients with critical limb
ischemia and a planned Phase 2b clinical trial in patients with
ischemic dilated cardiomyopathy. For more information, please visit
Aastrom's website at www.aastrom.com. For more information on
the pivotal REVIVE Phase 3 clinical trial, please visit the trial
website at www.revivecli.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements, including,
without limitation, statements concerning clinical trial plans and
progress, objectives and expectations, clinical activity timing,
intended product development, the performance and contribution of
certain individuals and expected timing of collecting and analyzing
treatment data, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made
through the use of words or phrases such as "anticipates,"
"intends," "estimates," "plans," "expects," "we believe," "we
intend," and similar words or phrases, or future or conditional
verbs such as "will," "would," "should," "potential," "could,"
"may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with clinical
trial and product development activities, regulatory approval
requirements, competitive developments, and the availability of
resources and the allocation of resources among different potential
uses. These and other significant factors are discussed in greater
detail in Aastrom's Annual or Transition Report on Form 10-K or
10-K/T, Quarterly Reports on Form 10-Q and other filings with the
Securities and Exchange Commission. These forward-looking
statements reflect management's current views and Aastrom does not
undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date of this release except as required by law.
CONTACT: Media contact
Andrea Coan
Berry & Company
acoan@berrypr.com
(212) 253-8881
Investor contact
Danielle Spangler
The Trout Group
dspangler@troutgroup.com
(646) 378-2924
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024